Last reviewed · How we verify
Alclometasone cream
Glucocorticoid receptor agonist
Glucocorticoid receptor agonist Used for Atopic dermatitis, Psoriasis, Seborrheic dermatitis.
At a glance
| Generic name | Alclometasone cream |
|---|---|
| Sponsor | Pfizer |
| Drug class | Corticosteroid |
| Target | Glucocorticoid receptor |
| Modality | Small molecule |
| Therapeutic area | Dermatology |
| Phase | Phase 2 |
Mechanism of action
Alclometasone cream is a topical corticosteroid that acts as a glucocorticoid receptor agonist, reducing inflammation and immune responses in the skin.
Approved indications
- Atopic dermatitis
- Psoriasis
- Seborrheic dermatitis
Common side effects
- Skin atrophy
- Hypersensitivity
Key clinical trials
- Study Of Dacomitinib (PF-00299804) In Advanced NSCLC Patients (Post Chemo Or Select First Line) To Evaluate Prophylactic Intervention On Derm And GI AEs And PRO (PHASE2)
- Study to Evaluate Product Duration of Use Experience With Alclometasone Dipropionate Cream (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Alclometasone cream CI brief — competitive landscape report
- Alclometasone cream updates RSS · CI watch RSS
- Pfizer portfolio CI